Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
出版年份 2017 全文链接
标题
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
作者
关键词
-
出版物
MODERN PATHOLOGY
Volume 31, Issue 1, Pages 24-38
出版商
Springer Nature
发表日期
2017-11-17
DOI
10.1038/modpathol.2017.104
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features
- (2017) Emily A Merkel et al. LABORATORY INVESTIGATION
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma
- (2016) L Manfredi et al. ACTA DERMATO-VENEREOLOGICA
- D03*Liver resection for colorectal liver metastases: can we cure our patients?
- (2016) D. Ribero et al. ANNALS OF ONCOLOGY
- B-Raf Inhibition in the Clinic: Present and Future
- (2016) Warren Fiskus et al. Annual Review of Medicine
- Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
- (2016) Laura Schirosi et al. BMC CANCER
- BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival
- (2016) Emilia Hugdahl et al. BRITISH JOURNAL OF CANCER
- Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
- (2016) Liqiang Xi et al. CLINICAL CANCER RESEARCH
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies
- (2016) Selma Ugurel et al. EUROPEAN JOURNAL OF CANCER
- Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
- (2016) Sarah J. Welsh et al. EUROPEAN JOURNAL OF CANCER
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
- (2016) Claus Garbe et al. EUROPEAN JOURNAL OF CANCER
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Overall Survival and Durable Responses in Patients WithBRAFV600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- (2016) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature
- (2016) Muhammad Ahmed Farooq Anwar et al. JOURNAL OF SURGICAL RESEARCH
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Coming of age: ten years of next-generation sequencing technologies
- (2016) Sara Goodwin et al. NATURE REVIEWS GENETICS
- The state of melanoma: challenges and opportunities
- (2016) Glenn Merlino et al. Pigment Cell & Melanoma Research
- Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
- (2016) Mack Y. Su et al. PLOS MEDICINE
- Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma
- (2016) Guo Chen et al. JAMA Oncology
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction
- (2015) Gatien Moriceau et al. CANCER CELL
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials
- (2015) A. Santiago-Walker et al. CLINICAL CANCER RESEARCH
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients
- (2015) Sharon K. Huang et al. Molecular Oncology
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- (2015) M. R. Girotti et al. Cancer Discovery
- BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
- (2015) Caterina Chiappetta et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- BRAFV600EProtein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
- (2015) Hanna Eriksson et al. JAMA Dermatology
- Melanoma
- (2015) Dirk Schadendorf et al. Nature Reviews Disease Primers
- The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
- (2014) Boris C. Bastian Annual Review of Pathology-Mechanisms of Disease
- Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAFmutations
- (2014) Michaela Angelika Ihle et al. BMC CANCER
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
- (2014) H. Rizos et al. CLINICAL CANCER RESEARCH
- Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach
- (2014) Joshua R. Bradish et al. HUMAN PATHOLOGY
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- (2014) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of the VE1 immunostain for theBRAFV600E mutation in melanoma
- (2014) Michelle V. Pearlstein et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy
- (2014) Joshua R Bradish et al. MODERN PATHOLOGY
- Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
- (2014) Alain R Thierry et al. NATURE MEDICINE
- Pragmatic issues in biomarker evaluation for targeted therapies in cancer
- (2014) Armand de Gramont et al. Nature Reviews Clinical Oncology
- Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
- (2014) Georgina V. Long et al. Nature Communications
- High-Resolution Melting Analysis for accurate detection of BRAF mutations: a systematic review and meta-analysis
- (2014) Dong Chen et al. Scientific Reports
- Fundamentals of Pyrosequencing
- (2013) Colleen T. Harrington et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Detection ofBRAFp.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility
- (2013) Cristi Marin et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations
- (2013) L Heinzerling et al. BRITISH JOURNAL OF CANCER
- Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations
- (2013) Joshua R Bradish et al. Future Oncology
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of BRAF V600 Mutations in Metastatic Melanoma
- (2013) Kevin Qu et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Comparison of Testing Methods for the Detection of BRAF V600E Mutations in Malignant Melanoma: Pre-Approval Validation Study of the Companion Diagnostic Test for Vemurafenib
- (2013) Fernando Lopez-Rios et al. PLoS One
- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
- (2012) Georgina V. Long et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of BRAF p.V600E Mutations in Melanomas
- (2012) Emeline Colomba et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- NRAS mutant melanoma: biological behavior and future strategies for therapeutic management
- (2012) I V Fedorenko et al. ONCOGENE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF targeted therapy changes the treatment paradigm in melanoma
- (2011) Antoni Ribas et al. Nature Reviews Clinical Oncology
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Immunohistochemistry for Biomarker Assessment—Can It Compete with Other Technologies?
- (2011) Robert W. Dunstan et al. TOXICOLOGIC PATHOLOGY
- Validation of Analytic Methods for Biomarkers Used in Drug Development
- (2008) C. H. Chau et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now